Bilateral hyperactive labyrinth

Summary

Bilateral hyperactive labyrinth (MONDO:0001897) is a disease. A subtype of inner ear disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bilateral hyperactive labyrinth
Mondo ID	MONDO:0001897
DOID	DOID:14165
SNOMED CT	194373002
UMLS	C0155516
MedGen	510002
Is cancer (heuristic)	no

Also known as: hyperactive labyrinth, bilateral

Disease family

This is a subtype of inner ear disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › auditory system disorder › inner ear disorder › bilateral hyperactive labyrinth

Related subtypes (14): labyrinthine bilateral reactive loss, labyrinthitis, labyrinthine unilateral reactive loss, unilateral hyperactive labyrinth, vestibular disorder, cochlear disorder, bilateral hypoactive labyrinth, unilateral hypoactive labyrinth, otosclerosis, motion sickness, X-linked mixed hearing loss with perilymphatic gusher, autoimmune inner ear disease, enlarged vestibular aqueduct syndrome, inner ear neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.